Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T12:01:08.319Z.
Calculation as of: 2026-10-06T12:01:08.319Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2c805ffacfcdae638738386c116dc6e6f159143ed75419b2c785d409d5d1ab78
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$25.48M
EV/EBIT Ratio
N/A
TTM Avg
11456.84x
3Y Avg
11456.84x
5Y Avg
11456.84x
Market Cap
$21.90M
EV/EBIT Ratio
N/A
TTM Avg
21.00x
3Y Avg
21.00x
5Y Avg
21.00x
Market Cap
$18.82M
EV/EBIT Ratio
N/A
TTM Avg
64.12x
3Y Avg
126.81x
5Y Avg
126.81x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $24.44M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.48M | N/A | 11456.84x | 11456.84x | 11456.84x |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | N/A | 21.00x | 21.00x | 21.00x |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $18.82M | N/A | 64.12x | 126.81x | 126.81x |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.65M | N/A | 0.37x | 0.82x | 0.82x |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
